WallStSmart

Abbott Laboratories (ABT)vsBruker Corporation (BRKR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1213% more annual revenue ($45.13B vs $3.44B). ABT leads profitability with a 13.9% profit margin vs -0.3%. ABT appears more attractively valued with a PEG of 1.29. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

BRKR

Hold

42

out of 100

Grade: D

Growth: 5.3Profit: 3.5Value: 5.7Quality: 5.3
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
BRKRUndervalued (+27.9%)

Margin of Safety

+27.9%

Fair Value

$58.89

Current Price

$44.16

$14.73 discount

UndervaluedFair: $58.89Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

BRKR1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

BRKR4 concerns · Avg: 2.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-0.4%2/10

ROE of -0.4% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : BRKR

The strongest argument for BRKR centers on Price/Book.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : BRKR

The primary concerns for BRKR are PEG Ratio, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while BRKR is a turnaround play — different risk/reward profiles.

BRKR carries more volatility with a beta of 1.12 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 42/100). BRKR offers better value entry with a 27.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Bruker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?